{"entity":{"id":"ro7771950","kind":"drug","name":"RO7771950","aka":["ZN-A-1041"],"tldr":"RO7771950 is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.","summary":"RO7771950 (A-1041, RG6596) is a small-molecule drug developed by Hoffmann-La Roche. Its target is HER2 (the sponsor names HER2). The sponsor states: A blood-brain-barrier-penetrant HER2-targeted inhibitor, studied orally in combination with trastuzumab and capecitabine in HER2-positive breast cancer, including patients with CNS metastases. ClinicalTrials.gov describes the intervention as: Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07413939 (RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07413939, plans to enrol 650 participants with primary completion expected 2029-05-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of RO7771950","url":"https://clinicaltrials.gov/search?intr=A-1041"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07413939","nct05593094"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"A-1041, RG6596","modality":"small molecule","mechanism":"A blood-brain-barrier-penetrant HER2-targeted inhibitor, studied orally in combination with trastuzumab and capecitabine in HER2-positive breast cancer, including patients with CNS metastases.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ro7771950/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/"},{"id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/"}]}}